98%
921
2 minutes
20
Objectives: This study assessed the needs, perceptions, and challenges associated with telemedicine in the treatment of oligoarticular/polyarticular juvenile idiopathic arthritis (oJIA/pJIA) and childhood-onset systemic lupus erythematosus (cSLE) in Japan.
Methods: A nationwide survey was conducted using Google Forms targeting members of the Japan College of Rheumatology, the Paediatric Rheumatology Association of Japan, and paediatricians affiliated with core paediatric specialty training facilities.
Results: Responses were received from 128 physicians with 77%, 50%, 27%, and 21% of patients travelling for more than one hour, crossing prefectural borders, coming from areas with limited specialised care, and residing in remote islands and regions, respectively. The JCR board-certified rheumatologists are more likely to treat these patients. Telemedicine was expected to reduce travel time (92.2%) and consultation time (92.2%), while concerns included patients' preference for in-person consultations (89.8%) and perceived differences in the quality of care (86.7%). Telemedicine was supported by 71.9% of respondents for stable oJIA/pJIA cases and 76.3% for stable cSLE cases.
Conclusions: Many physicians support telemedicine for patients with oJIA/pJIA or cSLE who travel long distances. Further studies should explore the quality differences between telemedicine and in-person consultations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/mr/roaf075 | DOI Listing |
Lancet Oncol
September 2025
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Background: Select patients with metastatic clear-cell renal-cell carcinoma can be treated without systemic therapy, yet few studies have explored this population. We investigated the efficacy of metastasis-directed therapy without systemic therapy in oligometastatic clear-cell renal-cell carincoma.
Methods: This investigator-initiated single-arm, phase 2 trial enrolled patients aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-2, histologically confirmed clear-cell renal-cell carcinoma, and one to five metastases.
Ann Vasc Surg
September 2025
Department of Vascular Surgery, York & Scarborough Teaching Hospitals NHS Trust, York, UK.
Objectives: Vascular surgery (VS) is a high-risk specialty, with complex procedures and multi-morbid patients. Medicolegal claims offer insight into recurring clinical vulnerabilities. We aimed to analyse litigation trends in VS over the past decade in England, and the potential impact of the COVID-19 pandemic.
View Article and Find Full Text PDFJMIR AI
September 2025
Department of Anesteshiology, Perioperative and Pain Medicine, Mount Sinai, New York, NY, United States.
Background: Clinical notes house rich, yet unstructured, patient data, making analysis challenging due to medical jargon, abbreviations, and synonyms causing ambiguity. This complicates real-time extraction for decision support tools.
Objective: This study aimed to examine the data curation, technology, and workflow of the named entity recognition (NER) pipeline, a component of a broader clinical decision support tool that identifies key entities using NER models and classifies these entities as present or absent in the patient through an NER assertion model.
Int J Med Inform
August 2025
National Engineering Laboratory for Internet Medical Systems and Applications, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Electronic address:
Purpose: Ensuring medication safety remains a pressing challenge in fragmented healthcare systems, particularly with the rapid growth of Internet Hospitals and limited pharmacist resources. Existing prescription review tools are often siloed and lack cross-institutional scalability. This study presents a cloud-based, dual-layer prescription review system (CEPR) designed to support provincial integration across Internet and outpatient care.
View Article and Find Full Text PDFIntroduction: Donanemab is an immunoglobulin G1 antibody that targets an N-terminal truncated form of amyloid beta present in mature plaques. Treatment-emergent (TE) anti-drug antibodies (ADAs) were quantified in donanemab-treated participants from two pivotal clinical trials, and effects of TE ADAs on donanemab pharmacokinetics, efficacy, and safety were assessed.
Methods: Data were pooled from the phase 2 TRAILBLAZER-ALZ (NCT03367403) and phase 3 TRAILBLAZER-ALZ 2 trials (NCT04437511).